MX2010009727A - Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos. - Google Patents

Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos.

Info

Publication number
MX2010009727A
MX2010009727A MX2010009727A MX2010009727A MX2010009727A MX 2010009727 A MX2010009727 A MX 2010009727A MX 2010009727 A MX2010009727 A MX 2010009727A MX 2010009727 A MX2010009727 A MX 2010009727A MX 2010009727 A MX2010009727 A MX 2010009727A
Authority
MX
Mexico
Prior art keywords
nicotinic acetylcholine
diazabicycloal
kanes
compounds
acetylcholine receptor
Prior art date
Application number
MX2010009727A
Other languages
English (en)
Inventor
Lan Miao
Balwinder Singh Bhatti
Anatoly Mazurov
Philip S Hammond
Srinivisa Rao Akireddy
V Srinivasa Murthy
Scott R Breining
Matt S Melvin
Yun-De Xiao
Ronald Joseph Heemstra
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of MX2010009727A publication Critical patent/MX2010009727A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con compuestos de la siguiente fórmula (I), (ver fórmula (I)) que se unen a, y modulan la actividad de los receptores nicotínicos neuronales de la acetilcolina, con procesos para preparar estos compuestos, con composiciones farmacéuticas que contienen estos compuestos, y con métodos para utilizar estos compuestos para tratar una amplia variedad de condiciones y trastornos, incluyendo aquellos asociados con la disfunción del sistema nervioso central (CNS).
MX2010009727A 2008-03-05 2009-03-04 Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos. MX2010009727A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3395908P 2008-03-05 2008-03-05
PCT/US2009/036009 WO2009111550A1 (en) 2008-03-05 2009-03-04 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes

Publications (1)

Publication Number Publication Date
MX2010009727A true MX2010009727A (es) 2010-09-28

Family

ID=40566370

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009727A MX2010009727A (es) 2008-03-05 2009-03-04 Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos.

Country Status (11)

Country Link
US (1) US20110071180A1 (es)
EP (1) EP2257549A1 (es)
JP (1) JP2011513421A (es)
KR (1) KR20100122508A (es)
CN (1) CN101959888A (es)
AU (1) AU2009221860A1 (es)
CA (1) CA2716863A1 (es)
IL (1) IL207678A0 (es)
MX (1) MX2010009727A (es)
RU (1) RU2010140613A (es)
WO (1) WO2009111550A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509982A1 (en) 2009-12-07 2012-10-17 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
NZ603966A (en) * 2010-05-27 2015-03-27 Targacept Inc Nicotinic receptor non-competitive antagonists
CN102875550B (zh) * 2011-07-12 2016-01-06 常州合全药业有限公司 1,3,7-三取代-3,7-二氮杂双环[3,3,1]壬烷衍生物及制备方法
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
MX2015017961A (es) * 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
EP3848028B9 (en) 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
JP7177825B2 (ja) 2017-08-29 2022-11-24 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) * 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) * 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
SK11402000A3 (sk) * 1998-02-04 2001-03-12 Banyu Pharmaceutical Co., Ltd Cyklické n-acylaminoderiváty
US5952339A (en) * 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
GB9821503D0 (en) * 1998-10-02 1998-11-25 Novartis Ag Organic compounds
WO2001044243A2 (en) * 1999-12-14 2001-06-21 Neurosearch A/S Novel heteroaryl-diazabicycloalkanes
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MXPA03008109A (es) * 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
CN1950082B (zh) * 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
CN101065385A (zh) * 2004-07-22 2007-10-31 坎布里制药公司 治疗微生物感染的利福霉素衍生物
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
IL207678A0 (en) 2010-12-30
EP2257549A1 (en) 2010-12-08
AU2009221860A1 (en) 2009-09-11
JP2011513421A (ja) 2011-04-28
CA2716863A1 (en) 2009-09-11
RU2010140613A (ru) 2012-04-10
CN101959888A (zh) 2011-01-26
US20110071180A1 (en) 2011-03-24
WO2009111550A1 (en) 2009-09-11
KR20100122508A (ko) 2010-11-22

Similar Documents

Publication Publication Date Title
WO2010096384A3 (en) Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
MY152387A (en) Preparation and therapeutic applications of (2s,3r)-n-2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide
MX2010003375A (es) Derivados de 1h-indol-3-carboxilato de quinuclidin-4-ilmetilo como ligandos del receptor de acetilcolina alfa 7 nicotinico para el tratamiento de enfermedad de alzheimer.
MX2009012749A (es) Compuestos heterociclicos como moduladores positivos del receptor de glutamato metabotropico 2 (receptor mglu2).
UA98317C2 (ru) СОЕДИНЕНИЯ С АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ НИКОТИНОВОГО АЦЕТИЛХИНОЛИНОВОГО РЕЦЕПТОРА α7 (α7-NACHR), КОМПОЗИЦИЯ, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
MX2010005648A (es) Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina.
WO2012003418A3 (en) Functionally selective ligands of dopamine d2 receptors
ECSP12012023A (es) 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotínicos neuronales de acetilcolina
MX2007008328A (es) Antagonistas cxcr4 para el tratamiento de trastornos medicos.
MY148002A (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
ATE455114T1 (de) Enantiomerenreine chinuclidinyloxy-pyridazine und ihre verwendung als nikotin-acetylcholin- rezeptorliganden
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
MX2009008616A (es) Antagonistas del receptor de dopamina 2 de rapida disociacion.
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
WO2006105117A3 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
MY159040A (en) Compounds
UA98772C2 (ru) Производные циклопропиламина как модуляторы н3-гистаминового рецептора
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands
MX2012003394A (es) Analogos de la nicotinamida de o-bencilo como moduladores alostéricos positivos del mglur5.
PH12014500413A1 (en) 1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands
CY1115616T1 (el) Παρασκευη και θεραπευτικες εφαρμογες του (2s,3r)ν-2((3-πυρδινυλ)μεθυλ)-1-αζαδικυκλο[2.2.2]οκτ-3-υλ)-3,5-διφθοροβενζαμιδιου

Legal Events

Date Code Title Description
FA Abandonment or withdrawal